Need help? Text us and our team of experts will reply in minutes +00 00 00000
GLOW

GLOW

Blend

GLOW

Research Use Only

All products are intended solely for laboratory research and are not for human or animal consumption. By purchasing, the buyer agrees to use these products in compliance with all applicable laws.

GLOW Blend Overview

The GLOW Blend combines three synthetic peptides studied for their roles in molecular signaling and pathway dynamics: GHK-Cu, BPC-157, and TB-500. Together, these peptides are investigated for their influence on angiogenesis, extracellular matrix remodeling, and systemic signaling pathways. In laboratory and preclinical models, the combination provides a platform for exploring synergistic effects in matrix integrity, vascular formation, and molecular resilience.

Pickart L. et al. (2015)

History

The concept of the GLOW Blend arises from decades of research into individual signaling peptides. GHK-Cu was first identified in biological plasma samples in the 1970s and later studied for gene regulation and matrix remodeling activity. BPC-157 was synthesized in the 1990s as a gastric protein fragment analog and has since been researched for angiogenic and structural processes. TB-500, derived from thymosin beta-4, traces its research lineage to thymus peptide studies in the 1960s and is recognized for its effects on molecular migration and angiogenesis. Combined, these peptides represent a convergence of experimental research lines.

Sikiric P. et al. (1993)

GHK-Cu Structure

CAS #: 49557-75-7

Molecular Formula: C₁₄H₂₄CuN₆O₄

Molecular Weight: 340.9 g/mol

PubChem ID: 5311476

BPC-157 Structure

CAS #: 137525-51-0

CAS #: 49557-75-7

Molecular Formula: C₁₄H₂₄CuN₆O₄

Molecular Weight: 340.9 g/mol

PubChem ID: 5311476

BPC-157 Structure

CAS #: 77591-33-4

CAS #: 49557-75-7

Formula: C₂₁₂H₃₅₀N₅₆O₇₈S

Molecular Weight: 4963.5 g/mol

PubChem ID: 16132321

Research Findings

The GLOW Blend, which combines GHK-Cu, BPC-157, and TB-500, has been studied across structural, epithelial, vascular, and systemic models. Research highlights its activity in collagen organization, molecular migration, angiogenesis, and molecular signaling. Together, these peptides complement one another by engaging pathways linked to matrix remodeling, pathway dynamics, and resilience in preclinical settings.

Key Areas of Research:

  • Structural: Collagen, matrix, tendon/ligament

  • Epithelial: Migration, matrix signaling, follicle dynamics

  • Vascular: Angiogenesis, nitric oxide, formation

  • Systemic: Signaling, viability, pathway dynamics

Together, these findings suggest broad experimental potential for the GLOW Blend across multiple biological pathways. By combining structural support, vascular formation, and epithelial remodeling with systemic signaling, the GLOW Blend provides a versatile platform for research into molecular dynamics, matrix characterization, and overall biological resilience in laboratory settings.

Pickart L. et al., 2015

References

Pickart L. et al. (2015). GHK-Cu and regulation of multiple biological processes in aging and repair. BioMed Res Int.

Sikiric P. et al. (1993). A new gastric peptide, BPC-157, characterized and synthesized. Peptides, 14(1): 127–131. 

Goldstein A.L. et al. (2005). Thymosin beta-4 and tissue regeneration: potential mechanisms of action. Ann N Y Acad Sci.

Maquart F.X. et al. (1988). Stimulation of collagen synthesis by the tripeptide GHK in fibroblast cultures. FEBS Lett, 238(2):343–346.

Japjec M. et al. (2021). BPC-157 and tendon/ligament structural integrity in experimental models. Int J Mol Sci, 22(17):9397.

Smart N. et al. (2007). Thymosin beta-4 induces progenitor mobilization and neovascularization. Nature, 445(7124):177–182.

Philp D. et al. (2003). Thymosin beta-4 promotes dermal wound healing. J Invest Dermatol, 121(4):694–701. 

Hsieh M.J. et al. (2014). Pro-angiogenic and reparative effects of BPC-157 in preclinical models. J Mol Med, 92(5): 483–495.

Bock-Marquette I. et al. (2004). Thymosin beta-4 activates integrin-linked kinase and promotes cardiac repair. Nature, 432(7016):466–472.

Kang E.A. et al. (2020). BPC-157 protective effects on liver, kidney, and lung in ischemia–reperfusion injury. Int J Mol Sci, 21(12): 4232.

Our Process

View Products

STEP 1

Precision Lyophilization

Manufactured in a controlled U.S. facility under strict compounding standards.

STEP 2

Verified Purity

Every batch third-party tested with HPLC and mass spectrometry.

STEP 3

Same-Day Fulfillment

Orders dispatched same-day from our U.S. facility.

STEP 1

Precision Lyophilization

Manufactured in a controlled U.S. facility under strict compounding standards.

STEP 2

Verified Purity

Every batch third-party tested with HPLC and mass spectrometry.

STEP 3

Same-Day Fulfillment

Orders dispatched same-day from our U.S. facility.
Text us, our dedicated team is here to help
Orders dispatched same-day from our U.S. facility.
Text Us
Frequently Asked Questions

Orders dispatched same-day from our U.S. facility.

View Products

Each vial contains exactly what’s shown on the label. For example, a 10mg vial has exactly 10mg of lyophilized peptide. Researchers can divide it into smaller portions—like four 2.5mg measurements—but the total amount remains 10mg.

Peptides are supplied as lyophilized powder. They do not come reconstituted, and any extra supplies must be sourced separately for research applications.
In lyophilized powder form, peptides stay stable for up to 2 years. After reconstitution, it should be refrigerated and is generally stable for up to 2 months.

Products from Raw Peptides do not include usage instructions, as they are strictly for in vitro research and prohibited by law for human or animal use. Misuse or unlawful application will result in permanent denial of service.

Lyophilized peptides should be stored away from heat and light. Once reconstituted, they must be refrigerated to maintain stability and efficacy.